NEW YORK (GenomeWeb News) - Agendia's CupPrint microarray service has acquired Medical Device registration at the Dutch Healthcare Inspectorate, the company said today.

 
Agendia received CE registration for MammaPrint in 2005.
 
CupPrint is a test for cancer of unknown primary patients.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers suggest that genetic variations could influence the side effects people experience when using synthetic cannabinoids, the International Business Times reports.

An analysis has examined the makeup of researchers on Twitter and what they share, Nature News reports.

At Stat News, Jim Kozubek argues that the Broad Institute is pushing the boundary of what a nonprofit is.

In PNAS this week: gut microbes may affect honeybee weight, phenotype and gene expression changes in DiGeorge syndrome, and more.